Delaloge, S <br/><br/>
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  09 2016 
 - 1725-32 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw260  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Drug-Related Side Effects and Adverse Reactions--pathology<br/>Female<br/>Humans<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Receptor, ErbB-2--genetics<br/>Treatment Outcome